All In Biotech

Investigational drug · Phase 2

VERVE-102

Also called: LY4636581

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "VERVE-102"

First trial start

2026

Sep 24, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VERVE-102", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Atherosclerosis
  • Cardiovascular Disease
  • Hypercholesterolemia

Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "VERVE-102" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Atherosclerosis

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • LepodisiranLY3819469Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

  • YN001Phase 22 trials

    Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.